Acquisition momentum GlobalData’s acquisition of Deallus signals a shift in ownership and potential integration opportunities. This presents a need for clear alignment on competitive intelligence capabilities within the broader life sciences portfolio and potential upsell for expanded CI services or ongoing advisory engagements to ensure seamless continuity.

Life sciences CI strength Deallus specializes in competitive intelligence for pharma, biotech, and med-tech with therapy-area expertise in neuroscience, oncology, rare diseases, and vaccines. Sales teams can pursue partnerships around market landscape, pricing strategy, and portfolio optimization to support client decision making and R&D prioritization.

Global reach, global clients A global life sciences footprint with top-tier pharma and emerging biopharma clients indicates continued demand for international market insights, launch readiness, and cross-market analytics. Opportunities exist to offer regional market access, forecasting, and global portfolio strategy services.

Integrated services Deallus blends primary research, market landscaping, workshops, and forecasting to deliver bespoke solutions. This modular approach is attractive for clients seeking end-to-end CI support, enabling cross-sell into value and pricing, R&D strategy, and medical affairs analytics.

Growth signals Revenue range ($25M–$50M) and a mid-sized employee base (51–200) suggest room for scalable, repeatable engagements and transformation programs. Prospect targets include mid-to-large biopharma and med-tech firms seeking competitive intelligence as a core strategic capability.